# The Global Central Nervous System Biomarkers Market Is Expected to Grow at a 10.2% CAGR Throughout the Forecast Period - Published: 2026-11-11 - Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md) - Topics: [News](https://healthcarenews.io/news.md) - Source: https://healthcarenews.io/news/the-global-central-nervous-system-biomarkers-market-is-expected-to-grow-at-a-10-2-cagr-thr/ - Publication: Healthcare News - Publisher: Connectively (Terkel, Inc.) - Editorial policy: https://healthcarenews.io/editorial-policy/ [![The Business Research Company](https://www.einpresswire.com/image/medium/236757/tbrc.jpeg)](https://www.einpresswire.com/image/large/236757/tbrc.jpeg#1024x302) The Business Research Company [![Central Nervous System Biomarkers Market Overview](https://www.einpresswire.com/image/medium/1241573/central-nervous-system-biomarke.jpeg)](https://www.einpresswire.com/image/large/1241573/central-nervous-system-biomarke.png#1024x768) Central Nervous System Biomarkers Market Overview *The Business Research Company's The Global Central Nervous System Biomarkers Market Is Expected to Grow at a 10.2% CAGR Throughout the Forecast Period* **Expected to grow to $9.92 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%”** — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, November 11, 2026 /[EINPresswire.com](https://www.einpresswire.com/)/ -- "Understanding the [central nervous system biomarkers market](https://www.thebusinessresearchcompany.com/purchaseoptions?id=12632&slug=central-nervous-system-biomarkers-global-market-report) reveals a promising growth trajectory fueled by scientific advancements and rising healthcare needs. This sector plays a crucial role in diagnosing and managing neurological disorders, making it an essential part of modern medicine. Let’s explore the market’s current size, key growth drivers, regional outlook, and future trends shaping this dynamic field. Current and Projected Market Size of the Central Nervous System Biomarkers Market The market for central nervous system biomarkers has shown strong growth recently, with its size expected to rise from $6.14 billion in 2025 to $6.74 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.8%. This upward trend during the past years is largely due to the increasing prevalence of neurological disorders, improvements in neuroimaging and assay technologies, expanded clinical research activities in neurology, growing demand for monitoring disease progression, and a surge in biomarker validation studies. Download a free sample of the [central nervous system biomarkers market report](https://www.thebusinessresearchcompany.com/report/central-nervous-system-biomarkers-global-market-report): [https://thebusinessresearchcompany.com/sample\_request?id=51212763&type=smp&name=Central%20Nervous%20System%20Biomarkers%20Market%20Report%202026&utm\_source=EINPresswire&utm\_medium=Paid&utm\_campaign=Nov\_PR](https://thebusinessresearchcompany.com/sample_request?id=51212763&type=smp&name=Central%20Nervous%20System%20Biomarkers%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR) Looking ahead, the central nervous system biomarkers market is anticipated to expand rapidly, reaching $9.92 billion by 2030 with an accelerated CAGR of 10.2%. Factors contributing to this forecasted growth include rising investments in precision neurology, greater utilization of biomarkers for personalized medicine, enhanced adoption of AI-driven biomarker discovery methods, broader implementation of biomarker-guided clinical trials, and increasing regulatory acceptance of biomarker endpoints. Emerging trends during this period include a shift toward blood-based CNS biomarkers, an intensified focus on drug development pipelines, early detection of neurodegenerative diseases, growth in companion diagnostic biomarkers, and more comprehensive integration of multi-omics data. What Central Nervous System Biomarkers Represent Central nervous system (CNS) biomarkers are specific measurable indicators found within the CNS that provide critical insights into normal brain function, disease mechanisms, or treatment responses. These biomarkers serve multiple purposes such as aiding in the diagnosis or prediction of neurological disorders, monitoring disease progression, and forecasting patient responses to therapies, thereby forming the backbone of modern neurological healthcare. View the full central nervous system biomarkers market report: [https://thebusinessresearchcompany.com/report/central-nervous-system-biomarkers-global-market-report?utm\_source=EINPresswire&utm\_medium=Paid&utm\_campaign=Nov\_PR](https://thebusinessresearchcompany.com/report/central-nervous-system-biomarkers-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR) How Growing Neurological Disorders Are Driving Market Expansion The increasing prevalence of neurological diseases is a major factor fueling growth in the central nervous system biomarker market. Neurological disorders encompass a wide spectrum of conditions affecting the brain, spinal cord, and peripheral nerves. These disorders have diverse origins including genetic abnormalities, infections, autoimmune diseases, degenerative changes, tumors, vascular issues, and physical injuries. CNS biomarkers play a vital role in clinical settings by supporting diagnosis, assessing disease risk or prognosis, staging illness severity, and tracking how patients respond to treatments, making them indispensable for improving patient outcomes. For instance, data from April 2023 by the US Centers for Disease Control and Prevention highlights that Alzheimer’s disease currently impacts approximately 6.7 million Americans aged 65 and above, a number projected to almost triple to 14 million by 2060. Furthermore, the population living with Alzheimer’s doubles every five years after the age of 65. This escalating burden of neurological conditions underscores the growing need for CNS biomarkers, which is directly driving market growth. Which Geographical Area Is Expected to Lead Growth in the CNS Biomarkers Market In 2025, North America held the largest share of the central nervous system biomarkers market. However, the Asia-Pacific region is forecasted to experience the fastest growth during the coming years. The market report covers a wide range of regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, offering a comprehensive global perspective on market developments. The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables. Speak With Our Expert: Saumya Sahay Americas +1 310-496-7795 Asia +44 7882 955267 & +91 8897263534 Europe +44 7882 955267 Email: marketing@tbrc.info The Business Research Company - [www.thebusinessresearchcompany.com](http://www.thebusinessresearchcompany.com) Follow Us On: • LinkedIn: [https://in.linkedin.com/company/the-business-research-company](https://in.linkedin.com/company/the-business-research-company)" Oliver Guirdham The Business Research Company [+44 7882 955267]() [info@tbrc.info](mailto:info@tbrc.info) Visit us on social media: [LinkedIn](https://www.linkedin.com/company/the-business-research-company/) [Facebook](https://www.facebook.com/TheBusinessResearchCompany/) [X](https://twitter.com/tbrc_info) Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above. ![](https://www.einpresswire.com/tracking/article.gif?aid=954383642§ion=einpresswire&a=kIS8Dw3VN_3K9lia&r=Ohkp76qG8AiWTQ6s&i=i147G1WHuqiCmYKp) ## Related - [One-time base editing for sickle cell disease met its goal of a year free of severe crises, Beam says](https://healthcarenews.io/news/base-editing-for-sickle-cell-disease.md) - [A lab-grown blood vessel for dialysis patients whose fistulas fail is set for an FDA filing in November](https://healthcarenews.io/news/bioengineered-blood-vessel-for-dialysis-fda-filing.md) - [Half of myeloma patients given one CAR-T infusion after an early relapse were progression-free five years on](https://healthcarenews.io/news/car-t-first-relapse-myeloma-five-year-results.md) - [Stargardt disease has no approved treatment. A new trial tests a shot that limits vitamin A reaching the eye](https://healthcarenews.io/news/stargardt-disease-clinical-trial-city-rbp4.md)